High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates (Q33760671)

29 July 2017

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates (English)

1 reference

29 July 2017

E S Daar

1

1 reference

29 July 2017

X L Li

series ordinal

2

1 reference

29 July 2017

T Moudgil

series ordinal

3

1 reference

29 July 2017

D D Ho

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 September 1990

1 reference

Proceedings of the National Academy of Sciences of the United States of America

29 July 2017

1 reference

29 July 2017

87

1 reference

29 July 2017

6574-6578

1 reference

29 July 2017

17

1 reference

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

A soluble form of CD4 (T4) protein inhibits AIDS virus infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

Human immunodeficiency virus type 1 in a seronegative patient with visceral Kaposi's sarcoma and hypogammaglobulinemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

HIV infection is blocked in vitro by recombinant soluble CD4.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

Quantitation of human immunodeficiency virus type 1 in the blood of infected persons

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

Inhibition of soluble CD4 therapy by antibodies to HIV.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

Designing CD4 immunoadhesins for AIDS therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=54579

Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein

28 July 2018

1 reference

12 December 2020

Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization

1 reference

12 December 2020

Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations

1 reference

12 December 2020

Human recombinant soluble CD4 therapy

1 reference

12 December 2020

Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.87.17.6574

1 reference

29 July 2017

0 references

1 reference

29 July 2017

1 reference